Industry rejects FDA’s proposal for biosimilar product-specific guidance
Regulatory NewsEmily Hayes
Biologics/ biosimilars/ vaccinesGuidanceProduct developmentProduct LifecycleUnited StatesUS Food and Drug Administration (FDA)Regulatory NewsEmily HayesBiologics/ biosimilars/ vaccinesGuidanceProduct developmentProduct LifecycleUnited StatesUS Food and Drug Administration (FDA)